

Analysis of paraffin-embedded slides of esophageal carcinoma after different treatments using QuPath

Benjamin T. Igbo^{1,2}, Annett Linge^{1,2,3,4}, Theresa Suckert^{2,4}, Susanne Frosch³, Liane Stolz-Kieslich⁴, Esther G.C. Troost^{1,2,3,4,5}

1. Institute of Radiooncology - OncoRay, Helmholtz-Zentrum Dresden-Rossendorf, Rossendorf, Germany; 2. OncoRay - National Center for Radiation Research in Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Helmholtz-Zentrum Dresden - Rossendorf, Dresden, Germany; 3. Department of Radiotherapy and Radiation Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany; 4. German Cancer Consortium (DKTK), Partner Site Dresden, and German Cancer Research Center (DKFZ), Heidelberg, Germany; 5. National Center for Tumor Diseases (NCT), Partner Site Dresden, Germany; German Cancer Research Center (DKFZ), Heidelberg, Germany; Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany; and; Helmholtz Association / Helmholtz-Zentrum Dresden - Rossendorf (HZDR), Dresden, Germany

Introduction :

The microscopic tumor extension during or after radiochemotherapy and its correlation with the tumor microenvironment are presently unknown. This information is, however, crucial in the era of image-guided high-precision photon or particle therapy. Therefore, we analyzed immunohistochemically stained paraffin-embedded tumor resection specimen from esophageal carcinoma patients, having undergone neoadjuvant radiochemotherapy followed by resection (NRCT+R) or resection (R) alone. Both, the overall distribution as well as the co-localization of markers with hypoxic tumor subvolumes were assessed.

Patient characteristics and treatment regimen :

This project comprised of four patient cohorts [n=20; five NRCT+R and five R from each, squamous cell carcinoma (SCC) and adenocarcinoma (AC)]. The NRCT+R treated patients received an irradiation dose of 40 Gy in 2 Gy/day fractions over four weeks. The chemotherapy regime combined two different drugs, SCC patients received Cisplatin and 5-Fluorouracil (5-FU), while AC patients were treated with Carboplatin and Paclitaxel. All ten NRCT+R patients underwent surgery between five to seven weeks after the end of NRCT.

Materials and Methods




Fig. 1. Workflow for assessment of the percentage of tumor cells positive for a specific marker.




Fig. 2: Workflow for the determination of proliferation outside and inside of the hypoxic subvolume (HIF-1α) using the QuPath Distance to annotation command.

Results




Fig. 3: Squamous cell carcinoma cells positive for one of the assessed markers
* p<0.05 ** p<0.01 *** p<0.001: Mann-Whitney test




Fig. 4: Adenocarcinoma cells positive for a marker depending on hypoxia (HIF-1α)
* p<0.05 ** p<0.01 *** p<0.001: Mann-Whitney test

- In tumor resection of patients with SCC, the Ki67 and p53 tumor positive cells overall were statistically significantly lower in the NRCT+R than in the R cohort (Ki67: $p=0.021$, p53: $p=0.044$; Fig.3).
- Conversely, Ki67 or p53 tumor positive cells within hypoxic regions were statistically significantly lower in patients with AC having received NRCT+R compared to R (Ki67: $p=0.005$; p53: $p=0.003$; Fig.4).

Conclusion and Outlook:

In this cohort of esophageal carcinoma resection specimen, a quantification workflow to assess the microscopic tumor extension after different treatments [NRCT+R or R alone] was established. Changes in the tumor microenvironment induced by NRCT were detected in both SCC and AC. A larger study is planned to validate these preliminary results.